Nationaal Multiple Sclerose Centrum V.Z.W.
- Address
- Vanheylenstraat 16, 1820 Steenokkerzeel, Belgium
Nervous System Diseases
The Nationaal Multiple Sclerose Centrum V.Z.W. in Steenokkerzeel, Belgium, concentrates on multiple sclerosis research. Current studies evaluate the potential of remibrutinib to lower relapse rates. Another trial tests frexalimab for delaying disability progression in non‑relapsing secondary progressive disease.
- Comparative efficacy of novel oral agents versus established therapies
- Strategies to reduce confirmed relapses in relapsing disease
- Approaches to delay disability progression in secondary progressive forms
- Long‑term safety and tolerability monitoring of emerging treatments
With two dedicated investigators, the centre’s neurology department conducts focused trials that aim to improve outcomes for patients living with multiple sclerosis, while also contributing valuable data to the broader scientific community.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 1 therapeutic areas and 15 of 19 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 1 by active trials.
- 1Zenas Biopharma (USA) LLC2active
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Zenas Biopharma (USA) LLC2trials
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 307 other sites in Belgium
Therapeutic Area Benchmark — Belgium
Select a therapeutic area to compare against other sites in Belgium.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Belgium
Market Share
Country: Belgium
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Nationaal Multiple Sclerose Centrum V.Z.W.
lock Showing 1 of 5 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Randomized, Double-Blind Study Comparing Remibrutinib and Teriflunomide in Relapsing Multiple Sclerosis Patients, with Open-Label Remibrutinib Extension | Novartis Pharma AG | Phase III | Not Recruiting | Jun 2022 | — |
IMP list
lock Showing 1 of 19 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Teriflunomide | 2 | Unknown | 2022-06-22 | 2023-11-23 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.